Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2527
mi
from 98109
Tampa, FL
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1939
mi
from 98109
Louisville, KY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
1821
mi
from 98109
Shreveport, LA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1821
mi
from 98109
Shreveport, LA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
1720
mi
from 98109
St Louis, MO
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1720
mi
from 98109
St Louis, MO
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2413
mi
from 98109
Manhasset, NY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2413
mi
from 98109
Manhasset, NY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2358
mi
from 98109
Raleigh, NC
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2373
mi
from 98109
Philadelphia, PA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
2325
mi
from 98109
Burlington, VT
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2325
mi
from 98109
Burlington, VT
Parkinson's Disease Isradipine Safety Study
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
710 N. Lake Shore Dr.
1732
mi
from 98109
Chicago, IL
Parkinson's Disease Isradipine Safety Study
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
Updated: 1/1/1970
710 N. Lake Shore Dr.
1732
mi
from 98109
Chicago, IL
Early Parkinson's Disease (PD) Cross-Sectional
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Early Parkinson's Disease (PD) Cross-Sectional
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Philadelphia FIGHTS
2373
mi
from 98109
Philadelphia, PA
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Philadelphia FIGHTS
2373
mi
from 98109
Philadelphia, PA
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
University of Colorado at Denver and Health Sciences Center
1023
mi
from 98109
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
University of Colorado at Denver and Health Sciences Center
1023
mi
from 98109
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Mile High Research Center
1021
mi
from 98109
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Mile High Research Center
1021
mi
from 98109
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
CNI Movement Disorders Center
1024
mi
from 98109
Englewood, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
CNI Movement Disorders Center
1024
mi
from 98109
Englewood, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Suncoast Neuroscience Associates, Inc
2524
mi
from 98109
St. Petersburg, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Suncoast Neuroscience Associates, Inc
2524
mi
from 98109
St. Petersburg, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Univeristy of South Florida
2523
mi
from 98109
Tampa, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Univeristy of South Florida
2523
mi
from 98109
Tampa, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Detroit Clinical Research Center
1909
mi
from 98109
Novi, MI
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Detroit Clinical Research Center
1909
mi
from 98109
Novi, MI
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Atlanta VA Medical Center
2181
mi
from 98109
Decatur, GA
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Atlanta VA Medical Center
2181
mi
from 98109
Decatur, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Parkinson Institute
669
mi
from 98109
Sunnyvale, CA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Parkinson Institute
669
mi
from 98109
Sunnyvale, CA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
The Institute for Neurodegenerative Disorders
2432
mi
from 98109
New Haven, CT
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
The Institute for Neurodegenerative Disorders
2432
mi
from 98109
New Haven, CT
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Mayo Clinic - Jacksonville, Florida
2465
mi
from 98109
Jacksonville, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Jacksonville, Florida
2465
mi
from 98109
Jacksonville, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of South Flordia
2527
mi
from 98109
Tampa, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of South Flordia
2527
mi
from 98109
Tampa, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Emory Umiversity School of Medicine
2180
mi
from 98109
Atlanta, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Emory Umiversity School of Medicine
2180
mi
from 98109
Atlanta, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Pacific Health Institute
2678
mi
from 98109
Honolulu, HI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Pacific Health Institute
2678
mi
from 98109
Honolulu, HI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Northwestern University
1733
mi
from 98109
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Northwestern University
1733
mi
from 98109
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Boston Med Center
2485
mi
from 98109
Boston, MA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Boston Med Center
2485
mi
from 98109
Boston, MA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Michigan State University
1855
mi
from 98109
East Lansing, MI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Michigan State University
1855
mi
from 98109
East Lansing, MI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Park Nicolet Clinic
1385
mi
from 98109
Golden Valley, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Park Nicolet Clinic
1385
mi
from 98109
Golden Valley, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Minnesota Medical Center
1393
mi
from 98109
Minneapolis, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
1393
mi
from 98109
Minneapolis, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Washington University
1717
mi
from 98109
St. Louis, MO
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Washington University
1717
mi
from 98109
St. Louis, MO
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
2154
mi
from 98109
Rochester, NY
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
2154
mi
from 98109
Rochester, NY
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
1963
mi
from 98109
Cincinnati, OH
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Pittsburgh
2134
mi
from 98109
Pittsburgh, PA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Tennessee
1865
mi
from 98109
Memphis, TN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Tennessee
1865
mi
from 98109
Memphis, TN
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
Status: Archived
Oregon Health and Science University
147
mi
from 98109
Portland, OR
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
University of Alabama at Birmingham
2080
mi
from 98109
Birmingham, AL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
2080
mi
from 98109
Birmingham, AL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Veterans Affairs Medical Center - New York
2402
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - New York
2402
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Unversity of California, San Francisco
680
mi
from 98109
San Francisco, CA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
680
mi
from 98109
San Francisco, CA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Emory University
2178
mi
from 98109
Atlanta, GA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Emory University
2178
mi
from 98109
Atlanta, GA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Mount Sinai Hospital
2401
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
2401
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Baylor School of Medicine
1892
mi
from 98109
Houston, TX
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
1892
mi
from 98109
Houston, TX